Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

4(50.0%)

Phase 1

2(25.0%)

Phase 2

2(25.0%)

8Total

N/A(4)

Phase 1(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07131345Phase 1Not Yet Recruiting

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Role: lead

NCT06827145Phase 2Active Not Recruiting

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Role: lead

NCT06753968Not ApplicableCompleted

The Role of Natural Orifice Specimen Extraction Surgery (NOSES) in Treating Right-sided Colon Cancer

Role: lead

NCT06694129Not Yet Recruiting

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

Role: lead

NCT06362980Phase 1Recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Role: lead

NCT06414915Phase 2Not Yet Recruiting

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

Role: lead

NCT06362902Not ApplicableRecruiting

Laparoscopic Right Hemicolectomy With Transrectal Specimen Extraction for Colon Cancer

Role: lead

NCT06279299Not ApplicableRecruiting

Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing Laparoscopic Total Mesenteric Excision

Role: lead

NCT05830890Not ApplicableUnknown

Sentinel Lymph Node Biopsy in Rectal Cancer

Role: lead

NCT05526456Completed

Mapping of Lymph Node Metastasis and Survival For pN+ Superficial Esophageal Squamous Cell Carcinoma

Role: lead

All 10 trials loaded